Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effects of LY2409021 on the Liver

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01588366
First received: April 27, 2012
Last updated: September 10, 2013
Last verified: September 2013

April 27, 2012
September 10, 2013
April 2012
September 2013   (final data collection date for primary outcome measure)
  • Change from Baseline to Day 28 in hepatic lipid content [ Time Frame: Baseline, Day 28 ] [ Designated as safety issue: No ]
  • Change from Baseline to Day 28 in hepatic glycogen content [ Time Frame: Baseline, Day 28 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01588366 on ClinicalTrials.gov Archive Site
  • Change from Baseline to Day 28 in transaminase levels [ Time Frame: Baseline, Day 28 ] [ Designated as safety issue: Yes ]
  • Glucose response to an Arginine Stimulation Test (Part A) [ Time Frame: Baseline and Day 29 ] [ Designated as safety issue: No ]
  • Glucagon response to an Arginine Stimulation Test (Part A) [ Time Frame: Baseline and Day 29 ] [ Designated as safety issue: No ]
  • Insulin response to an Arginine Stimulation Test (Part A) [ Time Frame: Baseline and Day 29 ] [ Designated as safety issue: No ]
  • Change from Baseline to Day 28 in transaminase levels [ Time Frame: Baseline, Day 28 ] [ Designated as safety issue: Yes ]
  • Glucose response to an Arginine Stimulation Test [ Time Frame: Baseline and Day 29 ] [ Designated as safety issue: No ]
  • Glucagon response to an Arginine Stimulation Test [ Time Frame: Baseline and Day 29 ] [ Designated as safety issue: No ]
  • Insulin response to an Arginine Stimulation Test [ Time Frame: Baseline and Day 29 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
The Effects of LY2409021 on the Liver
Effects of LY2409021 on Hepatic Metabolism in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus

This is a study that involves multiple doses of study drug (60 mg of LY2409021, 15 mg of LY2409021 or placebo) taken as capsules by mouth on a daily basis for 28 days. This study will image the liver using magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) in healthy participants and in participants with type 2 diabetes mellitus, when they take LY2409021 to see if liver changes happen at the same time as changes in blood tests. This study is approximately 11 weeks long, not including screening. A screening appointment is required within 28 days prior to the start of the study.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Basic Science
Diabetes Mellitus, Type 2
  • Drug: Placebo
    Administered orally
  • Drug: LY2409021
    Administered orally
  • Placebo Comparator: Placebo
    Part A and B - Up to 4 capsules of placebo administered orally once a day for 28 days.
    Intervention: Drug: Placebo
  • Experimental: 15 mg LY2409021
    Part B - 1 capsule of 15 mg LY2409021 orally once a day for 28 days. (Arm added in September, 2012, per protocol amendment.)
    Intervention: Drug: LY2409021
  • Experimental: 60 mg LY2409021
    Part A - 4 capsules of 15 mg LY2409021 administered orally once a day for 28 days.
    Intervention: Drug: LY2409021
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
September 2013
September 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

For all participants:

  • Must be a male, or a female who cannot become pregnant, and who is either a healthy participant, or who has type 2 diabetes
  • Must have a body mass index (BMI) of 18.5 to 29.9 kilograms per square meter (kg/m^2) if a healthy participant, or a BMI of 18.5 to 35.0 kg/m^2 if diabetic

For participants with type 2 diabetes mellitus (T2DM):

- On diet and exercise treatment, or taking metformin

Exclusion Criteria:

For all participants:

  • Have signs or symptoms of liver disease
  • Are infected with hepatitis B or hepatitis C
  • Have donated more than 450 mL of blood in the last 3 months or if have donated any blood in the last month
  • Smoke more than 10 cigarettes per day or are not willing to abstain from smoking while at the clinic
  • Have had surgery with metallic clips, staples or stents, or have had a cardiac pacemaker (or other surgical implants) inserted in any part of the body, or have fear of enclosed spaces or have symptoms that prevent them from being sent for an magnetic resonance imaging (MRI) scan

For participants with T2DM:

- Are using insulin

Both
21 Years to 70 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Singapore
 
NCT01588366
13107, I1R-FW-GLBK
No
Eli Lilly and Company
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP